- Home
- NXC vs CGTX Comparison
NXC vs CGTX Comparison
Compare NXC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- CGTX
- Stock Information
- Founded
- NXC 1992
- CGTX 2007
- Country
- NXC United States
- CGTX United States
- Employees
- NXC N/A
- CGTX N/A
- Industry
- NXC Investment Managers
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NXC Finance
- CGTX Health Care
- Exchange
- NXC Nasdaq
- CGTX Nasdaq
- Market Cap
- NXC 82.0M
- CGTX 20.5M
- IPO Year
- NXC N/A
- CGTX 2021
- Fundamental
- Price
- NXC $13.02
- CGTX $0.41
- Analyst Decision
- NXC
- CGTX Strong Buy
- Analyst Count
- NXC 0
- CGTX 5
- Target Price
- NXC N/A
- CGTX $5.63
- AVG Volume (30 Days)
- NXC 17.5K
- CGTX 2.0M
- Earning Date
- NXC 01-01-0001
- CGTX 08-07-2025
- Dividend Yield
- NXC 3.97%
- CGTX N/A
- EPS Growth
- NXC N/A
- CGTX N/A
- EPS
- NXC 0.19
- CGTX N/A
- Revenue
- NXC N/A
- CGTX N/A
- Revenue This Year
- NXC N/A
- CGTX N/A
- Revenue Next Year
- NXC N/A
- CGTX N/A
- P/E Ratio
- NXC $70.47
- CGTX N/A
- Revenue Growth
- NXC N/A
- CGTX N/A
- 52 Week Low
- NXC $11.86
- CGTX $0.22
- 52 Week High
- NXC $13.70
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- NXC 57.30
- CGTX 67.18
- Support Level
- NXC $12.97
- CGTX $0.29
- Resistance Level
- NXC $13.20
- CGTX $0.34
- Average True Range (ATR)
- NXC 0.13
- CGTX 0.03
- MACD
- NXC 0.03
- CGTX 0.01
- Stochastic Oscillator
- NXC 62.50
- CGTX 92.43
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.